当前位置: 首页 >> 检索结果
2241. Heparin and air filters reduce embolic events caused by intra-arterial cerebral angiography: a prospective, randomized trial.
作者: Martin Bendszus.;Martin Koltzenburg.;Andreas J Bartsch.;Roland Goldbrunner.;Thomas Günthner-Lengsfeld.;Franz X Weilbach.;Klaus Roosen.;Klaus V Toyka.;László Solymosi.
来源: Circulation. 2004年110卷15期2210-5页
Intra-arterial cerebral angiography is associated with a low risk for neurological complications, but clinically silent ischemic events after angiography have been seen in a substantial number of patients.
2242. Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure.
作者: Stefan Andreas.;Hartwig Reiter.;Lars Lüthje.;André Delekat.;Rolf W Grunewald.;Gerd Hasenfuss.;Virend K Somers.
来源: Circulation. 2004年110卷15期2157-62页
Patients with heart failure have high levels of central sympathetic outflow and also have a high prevalence of sleep-related breathing disorders, predominantly central sleep apnea. The options for treating central sleep apnea in heart failure are limited and include theophylline. Whether theophylline alters sympathetic activity in heart failure patients is not known.
2243. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease.
作者: Mark A Hlatky.;Derek B Boothroyd.;Kathryn A Melsop.;Maria M Brooks.;Daniel B Mark.;Bertram Pitt.;Guy S Reeder.;William J Rogers.;Thomas J Ryan.;Patrick L Whitlow.;Robert D Wiens.
来源: Circulation. 2004年110卷14期1960-6页
Coronary bypass surgery (CABG) and angioplasty (PTCA) have been compared in several randomized trials, but data about long-term economic and quality-of-life outcomes are limited.
2244. Role of coronary collaterals in off-pump and on-pump coronary bypass surgery.
作者: Hendrik M Nathoe.;Erik Buskens.;Erik W L Jansen.;Willem J L Suyker.;Pieter R Stella.;Jaap R Lahpor.;Wim-Jan van Boven.;Diederik van Dijk.;Jan C Diephuis.;Cornelius Borst.;Karel G M Moons.;Diederick E Grobbee.;Peter P T de Jaegere.
来源: Circulation. 2004年110卷13期1738-42页
Collaterals limit infarct size, preserve viability, and reduce mortality in patients with acute myocardial infarction. In patients with stable coronary disease, collaterals are associated with less angina and ischemia during angioplasty and fewer ischemic events during follow-up. The role of collaterals has not been studied in patients undergoing off-pump or on-pump bypass surgery.
2245. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
作者: Padma Kaul.;Paul W Armstrong.;Wei-Ching Chang.;C David Naylor.;Christopher B Granger.;Kerry L Lee.;Eric D Peterson.;Robert M Califf.;Eric J Topol.;Daniel B Mark.
来源: Circulation. 2004年110卷13期1754-60页
In a previous substudy of the GUSTO-I trial, we observed better functional and quality-of-life outcomes among patients in the United States (US patients) compared with patients in Canada. Rates of invasive therapy were significantly higher in the United States and were associated with a small mortality benefit (0.4%, adjusted P=0.02). We sought to determine whether Canadian-US differences in practice patterns in GUSTO-I had an impact on 5-year mortality.
2246. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
作者: Franz Hartmann.;Milton Packer.;Andrew J S Coats.;Michael B Fowler.;Henry Krum.;Paul Mohacsi.;Jean L Rouleau.;Michal Tendera.;Alain Castaigne.;Stefan D Anker.;Ildiko Amann-Zalan.;Silke Hoersch.;Hugo A Katus.
来源: Circulation. 2004年110卷13期1780-6页
The utility of N-terminal proBNP (NT-proBNP) to predict the occurrence of death and hospitalization was prospectively evaluated in the COPERNICUS study, which enrolled patients with an ejection fraction <25% and symptoms of chronic congestive heart failure at rest or on minimal exertion.
2247. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass.
作者: Harold L Lazar.;Paula M Bokesch.;Frederick van Lenta.;Carmel Fitzgerald.;Constance Emmett.;Henry C Marsh.;Una Ryan.; .
来源: Circulation. 2004年110卷11 Suppl 1期II274-9页
This study was undertaken to determine whether soluble human complement receptor type 1 (TP10), a potent inhibitor of complement activation, would reduce morbidity and mortality in high-risk patients undergoing cardiac surgery on cardiopulmonary bypass (CPB).
2248. Selective antegrade cerebral perfusion attenuates brain metabolic deficit in aortic arch surgery: a prospective randomized trial.
作者: D K Harrington.;A S Walker.;H Kaukuntla.;R M Bracewell.;T H Clutton-Brock.;M Faroqui.;D Pagano.;R S Bonser.
来源: Circulation. 2004年110卷11 Suppl 1期II231-6页
Aortic arch surgery has a high incidence of brain injury. This may in part be caused by a cerebral metabolic deficit observed after hypothermic circulatory arrest (HCA). We hypothesized that selective antegrade cerebral perfusion (SACP) would attenuate this phenomenon.
2249. Prospectively randomized evaluation of stented xenograft hemodynamic function in the aortic position.
作者: Thomas Walther.;Sven Lehmann.;Volkmar Falk.;Sebastian Metz.;Nicolas Doll.;Ardawan Rastan.;Marika Viehweg.;Markus Richter.;Jan Gummert.;Friedrich W Mohr.
来源: Circulation. 2004年110卷11 Suppl 1期II74-8页
Standard stented aortic xenograft valves have not yet been compared regarding their hemodynamic function using a stratified intraoperative randomization protocol.
2250. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
作者: Giulio Guagliumi.;Gregg W Stone.;David A Cox.;Thomas Stuckey.;James E Tcheng.;Mark Turco.;Giuseppe Musumeci.;John J Griffin.;Alexandra J Lansky.;Roxana Mehran.;Cindy L Grines.;Eulogio Garcia.
来源: Circulation. 2004年110卷12期1598-604页
Biological age is a strong determinant of prognosis in patients with acute myocardial infarction (AMI). We sought to examine the impact of age after primary percutaneous coronary intervention in AMI and to determine whether routine coronary stent implantation and/or platelet glycoprotein IIb/IIIa inhibitors improve clinical outcomes in elderly patients after primary angioplasty.
2251. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
作者: Sotirios Tsimikas.;Joseph L Witztum.;Elizabeth R Miller.;William J Sasiela.;Michael Szarek.;Anders G Olsson.;Gregory G Schwartz.; .
来源: Circulation. 2004年110卷11期1406-12页
Oxidized phospholipids (OxPL) are present within atherosclerotic plaques and bound by lipoprotein (a) [Lp(a)] in plasma. This study evaluated the impact of atorvastatin on oxidized LDL (OxLDL) in patients with acute coronary syndromes (ACS).
2252. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
作者: Koon K Teo.;L Brent Mitchell.;Janice Pogue.;Jackie Bosch.;Gilles Dagenais.;Salim Yusuf.; .
来源: Circulation. 2004年110卷11期1413-7页
ACE inhibitor therapy reduces the risk of cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure, and need for revascularization in high-risk patients with clinical heart failure, overt left ventricular systolic dysfunction, or vascular disease. In patients with clinical heart failure or overt left ventricular systolic dysfunction, ACE inhibitor therapy also reduces the risk of sudden or arrhythmia-related cardiac death. The objective of this study was to assess the effect of the ACE inhibitor ramipril on sudden unexpected death or resuscitated cardiac arrest among the 9297 individuals without clinical heart failure or overt left ventricular dysfunction enrolled in the Heart Outcomes Prevention Evaluation (HOPE) trial.
2253. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization.
作者: Joseph B Selvanayagam.;Attila Kardos.;Jane M Francis.;Frank Wiesmann.;Steffen E Petersen.;David P Taggart.;Stefan Neubauer.
来源: Circulation. 2004年110卷12期1535-41页
Despite the accepted utility of delayed-enhancement MRI in identifying irreversible myocardial injury, no study has yet assessed its role as a viability tool exclusively in the setting of coronary artery bypass surgery (CABG), and no study has repeated delayed-enhancement MRI late after revascularization. In a clinical trial in which patients underwent CABG by either the off-pump or on-pump surgical technique, we hypothesized that (1) preoperative delayed-enhancement MRI would have high diagnostic accuracy in predicting viability and (2) the occurrence of perioperative myocardial necrosis would affect late regional wall motion recovery.
2254. Increased sympathetic nerve activity in pulmonary artery hypertension.
作者: Sonia Velez-Roa.;Agnieszka Ciarka.;Boutaina Najem.;Jean-Luc Vachiery.;Robert Naeije.;Philippe van de Borne.
来源: Circulation. 2004年110卷10期1308-12页
This study tested the hypothesis that sympathetic nerve activity is increased in pulmonary artery hypertension (PAH), a rare disease of poor prognosis and incompletely understood pathophysiology. We subsequently explored whether chemoreflex activation contributes to sympathoexcitation in PAH.
2255. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
作者: M R Bristow.;H Krause-Steinrauf.;R Nuzzo.;Cheng-Seng Liang.;J Lindenfeld.;B D Lowes.;B Hattler.;W T Abraham.;L Olson.;S Krueger.;S Thaneemit-Chen.;J M Hare.;H S Loeb.;M J Domanski.;E J Eichhorn.;R Zelis.;P Lavori.
来源: Circulation. 2004年110卷11期1437-42页
Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent.
2256. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
作者: David J Wang.;Thomas C Dowling.;Dean Meadows.;Tomas Ayala.;Joanne Marshall.;Stacey Minshall.;Nancy Greenberg.;Emil Thattassery.;Michael L Fisher.;Krishnamurti Rao.;Stephen S Gottlieb.
来源: Circulation. 2004年110卷12期1620-5页
Nesiritide (synthetic human brain natriuretic peptide) is approved for the treatment of symptomatic heart failure. However, studies of brain natriuretic peptide in patients with heart failure have come to conflicting conclusions about effects on glomerular filtration rate (GFR), effective renal plasma flow, natriuresis, and diuresis.
2257. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME).
There are no prospective trial data on long-term outcomes in 80-year-old patients with chronic angina with regard to antiischemic therapy.
2258. Effect of isthmus anatomy and ablation catheter on radiofrequency catheter ablation of the cavotricuspid isthmus.
作者: Antoine Da Costa.;Emmanuel Faure.;Jérôme Thévenin.;Marc Messier.;Samuel Bernard.;Kihel Abdel.;Christophe Robin.;Cécile Romeyer.;Karl Isaaz.
来源: Circulation. 2004年110卷9期1030-5页
Cavotricuspid isthmus (CTI) characteristics are rarely documented when comparing catheters in radiofrequency ablation (RFA) of atrial flutter (AFL). Our objectives were (1) to evaluate the impact of CTI morphology and length on ablation procedures and (2) to compare the efficacy of an 8-mm-tip catheter with an irrigated cooled-tip RFA in the subgroup presumed to be more difficult to treat (with a long CTI, >35 mm).
2259. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
作者: Shinya Okazaki.;Takayuki Yokoyama.;Katsumi Miyauchi.;Kazunori Shimada.;Takeshi Kurata.;Hitoshi Sato.;Hiroyuki Daida.
来源: Circulation. 2004年110卷9期1061-8页
Recent clinical trials have demonstrated that aggressive lipid lowering by statins could prevent recurrent events after acute coronary syndrome (ACS). We hypothesized that this efficacy was caused by a significant reduction in plaque volume by aggressive LDL cholesterol (LCL-C) lowering. The present study investigated the effect of early statin treatment on plaque volume of a nonculprit lesion by serial volumetric intravascular ultrasound in patients with ACS.
2260. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
作者: Richard B Devereux.;Björn Dahlöf.;Eva Gerdts.;Kurt Boman.;Markku S Nieminen.;Vasilios Papademetriou.;Jens Rokkedal.;Katherine E Harris.;Jonathan M Edelman.;Kristian Wachtell.
来源: Circulation. 2004年110卷11期1456-62页
An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol.
|